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Abstract
Background: Pharmacokinetic (PK) data on amodiaquine (AQ) and artesunate (AS) are limited in
children, an important risk group for malaria. The aim of this study was to evaluate the PK
properties of a newly developed and registered fixed dose combination (FDC) of artesunate and
amodiaquine.
Methods: A prospective population pharmacokinetic study of AS and AQ was conducted in
children aged six months to five years. Participants were randomized to receive the new artesunate
and amodiaquine FDC or the same drugs given in separate tablets. Children were divided into two
groups of 70 (35 in each treatment arm) to evaluate the pharmacokinetic properties of AS and AQ,
respectively. Population pharmacokinetic models for dihydroartemisinin (DHA) and
desethylamodiaquine (DeAq), the principal pharmacologically active metabolites of AS and AQ,
respectively, and total artemisinin anti-malarial activity, defined as the sum of the molar equivalent
plasma concentrations of DHA and artesunate, were constructed using the non-linear mixed
effects approach. Relative bioavailability between products was compared by estimating the ratios
(and 95% CI) between the areas under the plasma concentration-time curves (AUC).
Results: The two regimens had similar PK properties in young children with acute malaria. The
ratio of loose formulation to fixed co-formulation AUCs, was estimated as 1.043 (95% CI: 0.956 to
1.138) for DeAq. For DHA and total anti-malarial activity AUCs were estimated to be the same.
Artesunate was rapidly absorbed, hydrolysed to DHA, and eliminated. Plasma concentrations were
significantly higher following the first dose, when patients were acutely ill, than after subsequent
doses when patients were usually afebrile and clinically improved. Amodiaquine was converted
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rapidly to DeAq, which was then eliminated with an estimated median (range) elimination half-life
of 9 (7 to 12) days. Efficacy was similar in the two treatments groups, with cure rates of 0.946 (95%
CI: 0.840–0.982) in the AS+AQ group and 0.892 (95% CI: 0.787 – 0.947) in the AS/AQ group. Four
out of five patients with PCR confirmed recrudescences received AQ doses < 10 mg/kg. Both
regimens were well tolerated. No child developed severe, post treatment neutropaenia (<1,000/
μL). There was no evidence of AQ dose related hepatotoxicity, but one patient developed an
asymptomatic rise in liver enzymes that was resolving by Day-28.
Conclusion: The bioavailability of the co-formulated AS-AQ FDC was similar to that of the
separate tablets for desethylamodiaquine, DHA and the total anti-malarial activity. These data
support the use this new AS-AQ FDC in children with acute uncomplicated falciparum malaria.
Background
Anti-malarial drug resistance in Plasmodium falciparum in
tropical countries has resulted in an increase in childhood
morbidity and mortality, especially in African under fives,
the most vulnerable group affected by falciparum malaria
[1]. Many countries are now switching or have switched
from ineffective monotherapies to reliably effective
artemisinin-based combination therapy (ACT) following
global recommendations by the World Health Organiza-
tion (WHO) [2].
The rationale for using ACT is based on the concept that
the artemisinin component will rapidly reduce parasitae-
mia leaving the residual parasitaemia to be cleared by
high concentrations of the partner drug. In this way, treat-
ment responses are rapid and reliable, and the probability
of the development of de novo resistance is greatly reduced
[2,3].
Rapid and effective treatment with ACT is considered
essential by the WHO for rolling back malaria, but treat-
ments are effective only if the full doses are taken. There is
increasing acceptance that adherence is improved by the
use of simplified, fixed dose combinations presented in
easy to use packaging [3,4].
Artesunate-amodiaquine is one of four ACT currently rec-
ommended by the WHO and is adopted as the first line
treatment in 18 African countries with a further three
countries where it is one of the first-line treatments [5].
Until recently AS + AQ has been available only as a loose
combination of the individual drugs, frequently in a co-
blister pack. Since ACT should be formulated as fixed dose
combinations (FDC), where possible [2], a co-formulated
AS/AQ product has been developed by a partnership, lead
by the Drugs for Neglected Diseases initiative (DNDi) with
the aim of making available an inexpensive, blister pack-
aged, new, simplified FDC dosing regimen based on age.
This new FDC has now been registered.
Although amodiaquine has been used extensively in
Africa for many years, there are very limited paeadiatric
and adult PK data. The present study was conducted as
part of the clinical development and registration of this
new FDC under well-established use. One key element
was to show whether the FDC had similar bioavailablity
to the presently used, loose AS + AQ regimen. Therefore,
the FDC was tested against loose AS + AQ in children
under five, with acute uncomplicated malaria in an open-
label, randomized comparative trial conducted in Burkina
Faso. The goal of the pharmacokinetic evaluation was to
assess the comparative bioavailability of the new FDC and
to characterize its pharmacokinetic properties.
Methods
This study was a part of the efficacy and safety evaluation
of new artesunate and amodiaquine (AS/AQ) FDC as
compared to the same drugs given separately (AS+AQ).
Results of the efficacy part of this evaluation have already
been reported [6]. The trial was conducted in Burkina
Faso, at the Healthcare District of Pissy between Septem-
ber and November 2006.
The study was approved by the Burkina Faso Ethics Com-
mittee for Health Research and the WHO Secretariat Com-
mittee on Research Involving Human Subjects and was
carried out in accordance with the ICH Guidelines for
Good Clinical Practice. Written informed consent was
obtained from parents or guardians before patients began
treatment. The trial is registered with the open clinical trial
registry [7] under the identifier number
ISRCTN07576538.
Patients of both sexes, between six months and five years
of age, weighing = 5 kg with Plasmodium falciparum
monoinfection of more than 1,000 parasites/μL and a
measured fever (axillary temperature ≥ 37.5°C) were
included in the study. Patients were excluded if they: (i)
had features of severe and complicated malaria [8]; (ii)
had taken the study drugs or other anti-malarial drugs
within seven days before inclusion (or within three days if
an artemisinin was used); or (iii) if they were receiving
treatment with antibiotics with anti-malarial activity. A
randomization list was computer generated. IndividualMalaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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treatment allocations were kept in sealed envelopes and
opened after patients were admitted into the study. All
treatments were administered by a study nurse. Fixed dose
combination (AS/AQ) was administered according to a
newly designed, age based dosing regimen [9] and loose
dose combination (AS+AQ) according to the manufac-
turer's instructions for the Arsucam® blister pack (Sanofi-
Aventis, Paris, France). For both regimens, the target doses
for artesunate and amodiaquine base were 4 mg/kg/day
and 10 mg/kg/day, respectively, with, therapeutic ranges
of 2 to 10 mg/kg/day and 7.5 to 15 mg/kg/day [9].
The FDC contained 25 mg of AS and 67.5 mg of AQ. The
dose was one (age <12 months) or two (age of 12 to 60
months) tablets. The loose blister pack contained 50 mg
tablets of AS (Arsumax®, Sanofi-Aventis) and 153 mg tab-
lets of AQ (Flavoquine®, Sanofi-Aventis). The dose was
half or one tablet of both drugs according to age, as
described above. Patients remained in the health centre
for an hour following each treatment administration.
Vomiting during this one hour observation period
resulted in re-administration of the same dose of the study
drugs.
Following the first visit, patients were seen after 24, 48,
and 72 hours, 7, 14, 21 and 28 days for clinical (symp-
toms, temperature, adverse effects) and parasitological
assessments. Parasite density was determined by counting
the number of asexual parasites per 200 leucocytes on a
Giemsa-stained thick film and expressed as the number/
μL, assuming a leukocyte count of 8,000/μL. If up to 500
parasites were counted before reaching 200 leucocytes,
the counting process was stopped at the end of the last
field. Gametocytes were counted and expressed as the
number per 1,000 leucocytes (thick film). Routine haema-
tology (Pentra 60®) and biochemistry (Hospitex Screen
Master Tecno®) blood samples were taken and analysed
on Days 0, 7 and 28.
Patients failing or not tolerating their treatment were
withdrawn from the study and rescued with 25 mg/kg/day
of oral or parental quinine base in three divided doses for
7 days. There was a systematic investigation of all patients
lost to follow-up.
Efficacy endpoints
The primary efficacy endpoint was the PCR corrected par-
asitological cure, assessed by Kaplan Meier survival analy-
sis. The criteria for treatment failure followed broadly
those of the WHO [8]: (i) signs of severe malaria or danger
signs at any time during follow up, (ii) parasitaemia at
Day-2 greater than parasitaemia at Day-0, (iii) Day-3 par-
asitaemia greater than or equal to 25% of parasitaemia
measured on Day-0, (iv) parasitaemia on Day-7, and (v) a
recurrent parasitaemia after Day-7 that was a PCR proven,
recrudescent parasitaemia.
Patients with recurrent parasitaemia after Day-7 were clas-
sified as failure or new infections by analysing sequen-
tially by PCR polymorphic segments of three parasite
genes: first the merozoite surface protein (MSP) 2, then
MSP 1 then glutamate rich protein (GLURP), according to
a previously published method [10]. A new infection was
diagnosed if the allelic pattern for any one of the loci dif-
fered completely between the baseline and recurrent sam-
ples. All other allelic patterns were diagnosed as a resistant
infection.
Safety of treatment was assessed by collecting clinical
(symptoms, signs) and routine laboratory data during fol-
low up. The standard International Conference on Har-
monisation (ICH) definitions of an adverse event and a
serious adverse event were used [11]. Adverse events crite-
ria were determined using the Common Toxicity Criteria
(US NIH, CTC v2 1999) and graded as mild (1), moderate
(2), severe (3) or very severe (4).
Sample size and sampling
A sample size of 140 children was deemed adequate for
the population PK model given the limitation of taking
blood from small children. Children were divided into
two groups of 70 (35 in each treatment arm). The first 70
recruited children formed the AS pharmacokinetics group.
All children were sampled three times: (i) before the first
dose, (ii) after the first dose, randomly at either 0.5, 1, 2
or 4 hours, (iii) after the third dose, randomly at either
0.5, 1, 2 or 4 hours. The second group (patients 71 to 140)
participated in the study of AQ pharmacokinetics. All chil-
dren were sampled four times: (i) before the first dose, (ii)
at 4 hours after the 3rd dose, (iii) on Day-7 or 14 of the fol-
low-up period, (iv) on Day-21 or 28 of the follow-up
period.
Each time, a sample of 1 mL of venous blood was col-
lected in lithium heparin tubes. Plasma was separated
immediately by centrifugation and stored frozen at
approximately -20°C until sample analysis within three
months.
Analytical methods
The concentrations of AS and AQ and their respective
pharmacologically active metabolites dihydroartemisinin
and desethylamodiaquine in plasma samples collected
during the study, were determined using sensitive and
specific Liquid Chromatography/Mass Spectrometry/
Mass Spectrometry (LC-MS/MS) methods developed and
validated by PAREXEL International.
Artesunate, dihydroartemisinin and the internal standard
(artesunate-D4) were separated from human plasma by
solid-phase extraction (SPE) using Oasis HLB C18 extrac-
tion cartridges and analysed by reversed-phase LC-MS/MS
in the Turbo Ion Spray positive mode. The assay was car-Malaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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ried out using a 200 μL sampling volume of human
plasma and the lower limit of quantification (LLOQ) of
the LC-MS/MS method was 1.0 ng/mL for both artesunate
and dihydroartemisinin. The coefficients of variations
(CV%) during the analysis of artesunate and dihydroar-
temisinin were 11.3% and 6.5% at low (3 ng/mL), 3.4%
and 5.0% at medium (100 ng/mL) and 3.9% and 9.0% at
high (200 ng/mL) concentrations.
Amodiaquine, desethylamodiaquine and the internal
standard (Amodiaquine-D10) were separated from
human plasma by a different solid-phase extraction (SPE)
using Oasis HLB C18 extraction cartridges and analysed
by reversed-phase LC-MS/MS in the Turbo Ion Spray pos-
itive mode. The assay was carried out using a 200 μL sam-
pling volume of human plasma and the lower limit of
quantification (LLOQ) of the LC-MS/MS method was 1.0
ng/mL of amodiaquine and desethylamodiaquine. The
CV% during the analysis of amodiaquine and desety-
lamodiaquine were 5.9% and 8.7% at low (3 ng/mL) and
6.3% and 8.0% at moderate (100 ng/mL) and 6.1% and
5.3% at high (200 ng/mL) concentrations.
Sample collection during this clinical study was per-
formed in lithium heparin tubes and did not include sta-
bilization with phenylmethyl sulfonylfluoride (PMSF).
Long term stability of amodiaquine and desethylamodi-
aquine in human plasma samples collected on lithium
heparin without PMSF was demonstrated for a 6-month
period at approximately -20°C [12].
Long term stability of artesunate and dihydroartemisinin
under these conditions [13] was demonstrated after 115
days of storage at -20°C. However, human plasma sam-
ples collected during this study were stored at -20°C for
up to 147 days prior to last sample analysis. This period of
storage is beyond the validated 16 weeks. Consequently,
the long-term stability of AS and its pharmacologically
active metabolite dihydroartemisinin in human plasma
with lithium heparin as anti-coagulant and without PMSF
was retested and demonstrated satisfactory stability for
artesunate containing samples for 173 days and dihy-
droartemisinin for 142 days for samples prepared as
described in the study.
The effects of haemolysis on the determinations were
investigated during the respective validation studies and
were found to have no effect on the assay of amodiaquine
and desethylamodiaquine. However, the assay of AS and
dihydroartemisinin was significantly affected in an unpre-
dictable way by haemolysis.
Therefore, the presence of evident haemolysis observed in
many of the plasma samples led to their classification as
not reportable (no quantitative result) for AS and dihy-
droartemisinin.
Pharmacokinetic analysis
Amodiaquine concentrations were usually low or not
detectable. The population pharmacokinetics of desethyl-
amodiaquine were modelled using the non-linear mixed
effects approach. One and two compartment models were
investigated. Due to the small number of detectable sam-
ples per subject (at most 3 per subject) and the timing of
samples, the absorption rate constant was fixed (as 0.13 h-
1 from previously published work [14]) and at most two
random effects which were not correlated could be fitted
at the same time. Children with detectable AQ concentra-
tions before the first dose were excluded from the analysis.
Children with detectable desethylamodiaquine levels and
corresponding negative AQ levels before the first dose
were included in the population modelling, and a first
order elimination process was assumed for these samples.
Pharmacokinetic parameters of DHA and the total anti-
malarial activity, defined as the sum of the plasma levels
of DHA and artesunate calculated in nmol/L units (taking
molecular weight as 384.4 for artesunate and 284.9 for
DHA) were also modelled (expressed as DHA equiva-
lents) using the population approach as described previ-
ously [15]. This assumes equal anti-malarial activity. A
one compartment model with three parameters (absorp-
tion rate constant, total apparent volume of distribution
(V/F) and total oral clearance CL/F) was fitted for each. It
was assumed that artesunate was completely converted to
DHA for determination of the dose in the pharmacoki-
netic analysis of DHA and of the total anti-malarial activ-
ity. Due to the small number of detectable samples (at
most 2 per subject, one after the first dose and one after
the third dose) only one random effect could be fitted.
Inter-subject variations in clearance and volume of distri-
bution were examined separately and in the final model,
the parameter with larger variation was fitted as a random
effect. The effect of the dosing period after which sam-
pling was done was examined by including a binary cov-
ariate (0 = sampling after dose 1/1 = sampling after dose
3) and was not accounted for by the random effects struc-
ture. Inter-subject variations in clearance and volume of
distribution were examined separately and in the final
model, the parameter with larger variation was fitted as a
random effect.
In each model, the inter-subject variability in pharmacok-
inetic parameters was modelled with a log-normal error
structure, for example: (CL/Fi) = (CL/F) exp(ηi
CL/F), where
CL/Fi is the parameter value for the ith individual, CL/F is
the population mean, ηi
CL/F is the random effect with zero
mean and variance σCL/F, which represents the inter-sub-
ject variability for the parameter. The magnitude of the
inter-subject variability was expressed as a coefficient of
variation (CV%) approximated by the square root of the
variance estimate, while the residual variability was
expressed as the standard deviation of the residual error.Malaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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The variability in pharmacokinetic parameters was inves-
tigated by examining the effects of the following covari-
ates: age, weight, temperature, respiratory rate, sex,
logarithm of enrolment parasitaemia, presence of game-
tocytaemia on enrolment, drug formulation and day of
measurement for DHA and total anti-malarial activity.
The log of the likelihood function was used to determine
which covariates should be included in the model, in the
forward selection procedure. The goodness of fit of each
model was also assessed by the examination of the scatter
plots of residuals versus predicted drug levels. The actual
time of the sampling was used in the analysis. All com-
partmental analyses were performed using the S plus pro-
gramme (SPLUS 6.0 for Windows, Mathsoft, Inc).
The final population models were used to calculate poste-
rior estimates of AUC for each individual based on the
actual dose received and based on the median total dose
received in this population (AUC = dose/clearance). The
AUCs were then compared between treatment arms by
calculating their ratio and the 95% CI.
Statistical methods
Data are summarized using medians and ranges. Contin-
uous variables were compared between treatment groups
using the Mann-Whitney test and categorical variables
were compared using the chi-square test or Fisher's exact
test, as appropriate.
Cure rates were estimated using the Kaplan-Meier
method. Patients who developed new infections during
the follow-up or were lost to the follow-up were censored
in the analysis at the last visit. Patients with recurrent par-
asitaemia and no PCR results were excluded from the
analysis. The difference in cure rates between treatments
was calculated and the 95% confidence interval was esti-
mated using Newcombe's method [16] and effective sam-
ple size [17].
Results
Of the randomized patients, 64 (45.7%) were females and
76 (54.3%) males. The median (range) age of patients at
baseline was 32 (7 – 59) months. There were no signifi-
cant differences between treatment groups at baseline for
all variables studied including demography (age, sex and
ethnic group), clinical variables (weight, temperature and
palpable spleen and liver), the measured parasitic varia-
bles and laboratory parameters. Demographic characteris-
tics and clinical parameters at baseline of patients
participating in the pharmacokinetic study are presented
in Table 1.
Efficacy analyses
Five patients (all in the FDC group) had early treatment
failure due to the development of severe malaria or danger
signs between Day-0 and Day-3. Twenty-three patients
had recurrent parasitaemia after Day-7: 12 from the AS/
AQ group and 11 from the AS+AQ group. Seventeen of the
23 recurrent cases had PCR samples analysed, for the
remaining patients the samples were missing. Of the 17
samples, eight (FDC AS/AQ) and four (AS+AQ) patients
were classified by PCR as new infections and five were
Table 1: Baseline characteristics. Median (range) or number of patients (%).
AS+AQ AS/AQ
Artesunate PK group N = 35 N = 35
Age (months) 37 (7 – 59) 32 (11 – 58)
Weight (kg) 14 (7 – 17) 12 (7.5 – 19)
Sex (n (%) males) 25 (71) 15 (43)
Temperature (°C) 39.0 (37.5 – 40.6) 38.7 (37.5 – 40.1)
Gametocytaemia
(n (%) with gametocytes)
6 (17) 3 (9)
Hepatomegaly (n (%)) 0 (0) 1 (3)
Splenomegaly (n (%)) 1 (3) 1 (3)
Parasite count (/μL) 30,000 (2000 – 162,000) 29,000 (2000 – 393,000)
Amodiaquine PK group N = 35 N = 35
Age (months) 26 (12 – 59) 29 (7 – 58)
Weight (kg) 12 (7 – 31) 12 (6 – 19)
Sex (n (%) males) 16 (46) 20 (57)
Temperature (°C) 38.4 (37.5 – 40.2) 38.4 (37.5 – 40.8)
Gametocytaemia
(n (%) with gametocytes)
1 (3) 7 (20)
Hepatomegaly (n (%)) 1 (3) 0 (0)
Splenomegaly (n (%)) 1 (3) 2 (6)
Parasite count (/μL) 29,600 (1000 – 170,000) 27,000 (1000 – 468,000)Malaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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classified as recrudescent infections (two from the AS/AQ
FDC group and three from the AS+AQ group).
Kaplan-Meier estimates of the cure rates (95% CI), after
adjusting for PCR results and excluding patients with
recurrent parasitaemia and no PCR result, were 0.946
(0.840–0.982) in the AS+AQ group and 0.892 (0.787 –
0.947) in the AS/AQ group. The estimated difference
(95% CI) in the cure rates was 0.053 (-0.051 to 0.154).
Clinical adverse events
By direct questioning, 87.1% (61/70) of patients in the
FDC AS/AQ group and 85.7% (60/70) in the AS+AQ
group reported at least one sign/symptom over the 28
days from a pre-defined list of 11 signs/symptoms (solic-
ited adverse events: weakness, headache, vertigo, abdom-
inal pain, anorexia, nausea, vomiting, diarrhoea,
coughing, rhinitis, cutaneous rash). None of these were
considered possibly or definitely related to the treatment.
The most frequent (>20%) solicited adverse events were
coughing, rhinitis, anorexia, diarrhoea and weakness.
There were three SAEs in the FDC AS/AQ treatment group:
(i) a 36-month old boy who died of severe malaria on
Day-0, (ii) a 21-month old girl who developed severe
anaemia on Day-1 that resolved on Day-3 (iii) a 36-
month old boy with gastroenteritis (salmonella) on Day-
14 that resolved on Day-26. For the AS+AQ treatment
group, a 26-month old girl had convulsions on Day-0 but
subsequently recovered. All SAEs were considered unre-
lated to study drugs.
The boy who died was previously well and presented with
a 24 hours history of fever and anorexia. On examination,
he was alert, febrile (38.7°C, axilla) and had pale con-
junctiva but was not jaundiced. His parasitaemia was
139,625/μL and his haemoglobin was 8.2 g/dl. An
uncomplicated malaria was diagnosed and treated with
paracetamol 250 mg and the FDC ASAQ 50 mg/135 mg.
Five hours later, he went into a coma and he was trans-
ferred to hospital with a diagnosis of severe malaria. His
temperature was 36.5°C; blood glucose 15.528 mg/dl,
haemoglobin 6.9 g/dl and had a parasitaemia of 85,546/
μL. He was treated with intravenous quinine but he died
several hours later. The drug concentrations measured two
hours after dosing were 620 ng/ml of DHA and 4.5 ng/ml
of artesunate.
Laboratory parameters
There were no differences between treatment groups with
respect to values of the laboratory parameters on Day-0,
Day-28 and with respect to their changes over time (all p
> 0.05, Kruskal-Wallis test). From baseline to Day-28, the
median (range) haematocrit increased from 26.5 (17.1 –
37.4)% to 32.0 (20.5 – 39.3)% and the median change
was 3.9 (-3.3 – 15.6)%. The median (range) platelet
counts rose from 173.0 (19.0 – 648.0) × 109/L to 391.0
(56.0 – 906.0) × 109/L, with the median (range) change of
218.0 (-242.0 – 692.0)/L.
Median Day-0 and Day-28 asparate aminotransferase
(AST) values were 62.8 (27.3 – 448.6) and 54.4 (4.9 –
824.2) IU/L, respectively with median (range) change: -
10.2 (-392.0 – 760.2) IU/L. Median total serum bilirubin
fell from 15.7 (0.3 – 73.2) to 3.4 (0.0 – 97.0) μmol/L
(median change: -10.0 [-68.6–85.2] μmol/L) and median
serum creatinine fell from 42.3 (14.1 – 71.6) to 34.8 (18.1
– 105.7) μmol/L (median change: -7.3 [-34.7–34.0]
μmol/L). Median serum alanine aminotransferase (ALT)
values changed little over time (23.9 [6.6–174.8] to 25.2
[12.5–759.9] IU/L) with the median (range) of 0.8 (-
149.6 – 724.5) IU/L.
One FDC group patient whose post Day-2 DeAQ concen-
tration was 616.8 ng/ml developed CTC grade 3 (> 5 – ≤
20 × ULN) liver enzymes during follow up (total bilirubin
values normal): AST = 64 IU/L (D0), 294 (D14), 352 IU/
L (D21) and 222 IU/L (D28). Corresponding ALT values
23, 389 and 227 IU/L. The patient's bilirubin levels were
normal during the whole follow-up period. All other
patients with DeAq levels > 600 ng/mL had normal bio-
chemical results.
Severe neutropaenia (defined as a neutrophil count of
<1000/μL) rates on Day-0 and Day-28 were 1/132 (0.8%)
and 0/84 (0.0%), respectively. Leukopaenia (WBC <6000/
μL for children <12 months, <5,000/μL for children
between 1 and 5 years) rates on Day-0 and Day-28 were 2/
135 (1.5%) and 0/85 (0.0%), respectively.
Pharmacokinetic analysis
Measured concentrations of desethylamodiaquine, DHA,
and AS in all patients are presented in Figures 1, 2 and 3;
concentrations of AQ and DeAq are summarized in Table
2. Seven patients were excluded (four in the AS PK group
and three in amodiaquine PK group) from the pharma-
cokinetic analysis since they vomited within one hour of
study drug administration. Two further patients were
excluded from the amodiaquine PK analysis since they
had positive AQ and desethylamodiaquine samples
before the first dose indicating a recent treatment with AQ
and it was impossible to assess how much drug has
already been absorbed.
Positive desethylamodiaquine levels, but negative corre-
sponding AQ levels, were detected in 28 patients (14 on
each treatment arm) before the first dose, suggesting pre-
vious AQ administration. These levels were modelled
assuming first order elimination of the previous dose, and
subtraction from the study drug profile.Malaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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One child, who received a total dose of 39 mg/kg, had a
very high plasma concentration of desethylamodiaquine
recorded 4 hours after the last dose (1308 ng/mL). How-
ever, the plasma concentration on Day-7 (142.6 ng/mL)
was within the range for other patients. This patient had a
low desethylamodiaquine concentration before the first
dose (18.5 ng/mL), which did not explain the subsequent
very high level.
Amodiaquine
In total 60 samples (31 in the AS+AQ group and 29 in the
AS/AQ group) had detectable levels of AQ, all taken at
approximately 4 hours (median [range] = 4 [3.9–4.8])
after the third dose, at similar times in the two treatment
groups (p = 0.35, Mann-Whitney test). These levels were
not significantly different between treatment arms (p =
0.9, Mann-Whitney test) median (range): 15.5 (3.8 –
48.9) and 14.1 (5.6 – 54.4) ng/mL, respectively.
Desethylamodiaquine
The pharmacokinetics of desethylamodiaquine was best
described by a two compartment open model with first
order absorption and elimination. The best fit was
obtained with concentration modelled on a log scale and
homoscedastic error model. The final estimates of the
pharmacokinetic parameters are presented in Table 3. Fig-
ure 4 shows residuals plots. A good agreement between
fitted and observed concentrations was achieved,
although there were a few outliers with very high concen-
trations (Figure 4A). There were no obvious patterns in
the residuals (Figure 4B), which satisfied the normality
assumption (Figure 4C). Inclusion of any of the covari-
ates, including drug formulation, into the population
Table 2: Plasma concentrations of amodiaquine and desethylamodiaquine
Median (Range) (N) Concentration (ng/mL)
AS+AQ AS/AQ
Amodiaquine
Pre-dose 1 3.54 (n/a) (1) 1.96 (n/a) (1)
Post-dose 3 15.0 (3.8 – 48.9) (32) 14.1 (5.6 – 54.4) (30)
Desethylamodiaquine
Pre-dose 1 7.7 (1.0 – 108.9) (15) 9.3 (1.6 – 137.1) (15)
Post-dose 3 396.6 (86.9 – 1307.8) (32) 347.1 (143.3 – 759.3) (30)
Day-7 73.9 (40.7 – 186.9) (15) 91.5 (31.4 – 235.2) (15)
Day-14 48.8 (11.7 – 84.1) (15) 41.0 (24.1 – 99.2) (16)
Day-21 29.0 (19.2 – 47.3) (10) 17.7 (9.3 – 48.0) (18)
Day-28 17.7 (5.4 – 100.1) (18) 17.4 (5.5 – 69.9) (12)
Measured concentrations of Desethylamodiaquine Figure 1
Measured concentrations of Desethylamodiaquine. 
Filled circles denote samples from patients in the FDC 
AS+AQ treatment arm and hollow circles denote samples 
from patients in the AS/AQ treatment arm.
Measured concentrations of Artesunate Figure 2
Measured concentrations of Artesunate. Filled circles 
denote samples from patients in the FDC AS+AQ treatment 
arm and hollow circles denote samples from patients in the 
AS/AQ treatment arm.Malaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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pharmacokinetic model did not reveal any statistically sig-
nificant associations with clearance.
There were no differences in the distribution of the poste-
rior individual estimates of total oral clearance (CL/F)
between the two treatment arms: mean (standard devia-
tion, CV%) 0.61 (0.11, 18%) L/kg/h in the loose formula-
tion arm and 0.63 (0.10, 15%) L/kg/h in the fixed
formulation arm; difference 0.024 (95%CI: -0.077 to
0.030) L/kg/h; normal distribution for the estimates could
be assumed. This reflected very similar AUCs in the two
treatment groups, normalized for an oral dose of 34 mg/
kg; median (range) of 57.76 (40.00 – 82.32) ng/mL.h
with the loose formulation arm and 54.75 (40.73 –
73.64) ng/mL.h with the fixed formulation. The ratio of
the loose formulation AUC to the fixed formulation AUC
was estimated as 1.043 (95% CI: 0.956 to 1.138).
However, the actual dose received was approximately
10% higher in the loose combination arm so the observed
AUCs were also higher: median (range) of 62.5 (24.4 –
95.3) ng/mL.h in the loose formulation group and 48.7
(39.0 – 92.3) ng/mL.h in the fixed formulation group (p
< 0.001).
In total fourteen patients in the group of patients with
measured desethylamodiaquine levels had recurrent para-
sitaemia: nine in the fixed dose combination group (two
recrudescences, six new infections and two with no PCR
results) and five in the loose combination group (three
recrudescences, one new infection and one with missing
PCR). Based on pharmacokinetic models these patients
had relatively low predicted concentrations of desethyl-
amodiaquine (Figure 5). Predicted concentrations at Day-
7 and Day-14 were significantly lower (p < 0.001 for both,
Kruskal-Wallis test) in patients with recurrent parasitae-
mia (Figure 6). Among patients with a recurrent parasitae-
mia, seven patients had measured drug concentrations on
Day-7 and another seven patients on Day-14. Five of the
measurements (71%) on Day-7 (median [range]: 53.2
[41.2–74.1] ng/mL) were below the median value for the
non-recurrent cases (median [range]: 95.1 [31.4–235.2]
ng/mL, n = 23). The other two cases with concentrations
(101.3 and 190.8 ng/mL) above the median were reinfec-
tions. Day-7 DeAq concentration was measured in three
out of five patients with PCR confirmed recrudescence
and they were all below 75 ng/mL giving an estimate of
the cure rate in patients with Day-7 concentrations above
75 ng/mL as 100%. For the estimated Day-7 concentra-
tions, only one (out of 5) patient with PCR confirmed
recrudescence has the value above 75 ng/mL (93 ng/mL),
which gives the corresponding cure rate of 97%.
Four of the seven (57%) measurements on Day-14
(median [range]: 25.4 [11.7–84.2] ng/mL) were below the
median value for the non-recurrent cases (median [range]
48.8 [25.2–99.2] ng/mL, n = 23), including the only PCR
confirmed recrudescence in this group. Four out of five
patients with PCR confirmed recrudescence received
doses below 10 mg/kg (4.9, 7.7 and two patients 9.0 mg/
kg) and their estimated clearance was at the 54th, 7th, 28th
and 67th  percentile, respectively (Figure 7). The fifth
patient, with a high dose (15.3 mg/kg), had relatively
rapid clearance at the 73rd percentile.
Artesunate and DHA
The pharmacokinetics of DHA and the total anti-malarial
activity were best described by a one compartment model
with volume of distribution fitted as a random effect, on
Measured concentrations of DHA Figure 3
Measured concentrations of DHA. Filled circles denote 
samples from patients in the FDC AS+AQ treatment arm 
and hollow circles denote samples from patients in the AS/
AQ treatment arm.
Table 3: Estimated pharmacokinetic parameters for 
desethylamodiaquine
Parameter Estimate (SE) Inter-subject variation CV%
Ka (h-1) 0.13 (fixed)
CL/F (L kg-1 h-1) 0.610 (0.038) 22.7%
Q (L kg-1 h-1) 0.680 (0.306)
Vcentral/F (L kg-1) 35.4 (11.5)
Vperipheral/F (L kg-1) 87.9 (17.1)
T 1/2 (days) 9.0 [7.3–11.6]1
σ 0.457
1range of predicted values;
Ka – absorption rate constant; CL/F – total clearance;
Q – inter-compartmental clearance; Vcentral/F – volume of the central 
compartment;
Vperipheral/F – volume of the peripheral compartment; F – fraction of 
drug absorbed;
σ – residual additive error on the loge scale.Malaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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the original scale and homoscedastic error model (Table
4). There was very little variation between subjects in esti-
mated total oral clearance (standard deviation <10-7), but
modelling clearance as a fixed parameter which differed
with dosing periods improved the model significantly (p
< 0.001 for both). This was justified by previous studies
which have shown disease related changes in the pharma-
c o k i n e t i c s  o f  t h e  A S  d e r i v a t i v e s  [ 1 8 , 1 9 ] .  S o m e  o f  t h e
between subject variation in volume of distribution could
be explained by age or weight (p < 0.001 for each, likeli-
hood ratio test) but the effect of these two covariates was
not independent (Table 4). Inclusion of any other covari-
ates, including drug formulation and dosing period, into
the population pharmacokinetic model did not reveal any
statistically significant associations with volume of distri-
bution. Plots of fitted and observed concentrations show
a reasonable agreement (Figures 8A and 9A). There were
no obvious patterns in residuals (Figures 8B and 9B) and
they satisfied the normality assumption (Figures 8C and
9C).
Since no differences in clearance for both DHA and anti-
malarial activity were found between treatment arms (p =
0.73 and p = 0.71 respectively), the corresponding AUCs
were estimated as 4.29 (95% CI = 3.48 – 5.59) ng/mL.h
and 4.43 (95% CI = 3.61 – 5.75) ng/mL.h after the first
dose for all patients, assuming a 3.7 mg/kg dose of AS.
After the third dose the clearance approximately doubled
so the AUCs were approximately halved: 1.96 (95% CI =
1.47 – 2.93) ng/mL.h and 2.14 (95% CI = 1.59 – 3.25) ng/
mL.h, for the same dose.
Residuals plots for the desethylamodiaquine pharmacokinetic population model: (A) observed versus fitted values; (B) residuals  versus the fitted values; (C) normal plot of residuals Figure 4
Residuals plots for the desethylamodiaquine pharmacokinetic population model: (A) observed versus fitted 
values; (B) residuals versus the fitted values; (C) normal plot of residuals.
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Predicted desethylamodiaquine (DeAq) concentrations from  the population model Figure 5
Predicted desethylamodiaquine (DeAq) concentra-
tions from the population model. Dark grey curves rep-
resent profiles for patients with recurrent parasitaemia.
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Predicted desethylamodiaquine (DeAq) levels at day-7 and  day-14 for patients who were cured and those who had  recurrent parasitaemia Figure 6
Predicted desethylamodiaquine (DeAq) levels at day-
7 and day-14 for patients who were cured and those 
who had recurrent parasitaemia.Malaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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Discussion
For diseases requiring treatment with a combination of
drugs, fixed combinations (FDC) are increasingly consid-
ered the optimum therapeutic approach. It is essential,
therefore, to confirm that the bioavailability of any newly
developed FDC is similar to that of the previously estab-
lished and validated loose drug combination in the dis-
ease being treated.
This population pharmacokinetic evaluation of two AS-
AQ regimens – one comprising loose tablets, and the
other a newly developed fixed dose co-formulation – indi-
cates that the two formulations have similar pharmacoki-
netic properties in young children with acute malaria, the
main target group for this treatment. Amodiaquine was
converted rapidly to desethylamodiaquine presumably by
hepatic metabolism in a "first pass" and so it is the metab-
olite, which contributes most of the anti-malarial activity
[20,21]. The estimated desethylamodiaquine half life of 9
(7 – 12) days is in broad agreement with previously pub-
lished estimates from studies in children with falciparum
malaria: median (range) of 7.4 (3.3 – 30.5) days [22]
from the individual patients analysis; range 3 – 12 days
from the population analysis [14]. Population analysis of
sparse data, in general, produces narrower ranges of esti-
mates since the extreme estimates observed in the individ-
ual patient analysis are shifted towards the population
mean. Modelling based on sparse data may also underes-
timate very long terminal elimination phases at low con-
centrations (although these may not be of relevance to the
immediate anti-malarial effect). There were no significant
differences in the main pharmacokinetic parameter esti-
Estimated desethylamodiaquine clearance and amodiaquine  dose received for: grey circles – patients without recurrence  of the parasitaemia; dark circles – patients with recrudes- cence; triangles – patients with reinfections and empty circles  – patients with recurrent infection without a PCR result Figure 7
Estimated desethylamodiaquine clearance and amo-
diaquine dose received for: grey circles – patients 
without recurrence of the parasitaemia; dark circles 
– patients with recrudescence; triangles – patients 
with reinfections and empty circles – patients with 
recurrent infection without a PCR result.
Table 4: Estimated dihydroartemisinin and total anti-malarial activity pharmacokinetic parameters.
Parameter Estimate (SE) Inter-subject variation CV%
DHA
Ka (h -1) 4.271 (2.091)
CL/F1 (L kg-1 h-1) 0.636 (0.075)
Increase in CL/F due to the 3rd dose period 0.760 (0.160)
V/F (L kg-1) 2.285 (0.317) 47%
Effect of Age on V/F 0.063 (0.015)
T 1/2 (h)
1st dose 2.5 [0.8–4.5]2
3rd dose 1.1 [0.4–2.0]2
σ (ng/mL) 340
Anti-malarial Activity
Ka (h-1) 4.744 (2.587)
CL/F1 (L kg-1 h-1) 0.616 (0.071)
Increase in CL/F due to the 3rd dose period 0.662 (0.150)
V/F (L kg-1) 2.134 (0.287) 48%
Effect of Age on V/F 0.063 (0.013)
T 1/2 (h)
1st dose 2.4 [0.5–5.7]2
3rd dose 1.2 [0.2–2.7]2
σ (ng/mL) 353
1population mean estimate of CL/F for the first dose period
290% range of predicted values;
Ka – absorption rate constant; CL/F – total clearance; V/F – volume of distribution; F – fraction of drug absorbed; σ – residual additive error in 
DHA unitsMalaria Journal 2009, 8:200 http://www.malariajournal.com/content/8/1/200
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mates between formulations, the ratio of AUC loose to
fixed formulation was 1.043 (0.956 – 1.138) for a nor-
malized total oral dose of 34 mg/kg.
In this study, measured concentrations of desethylamodi-
aquine had more symmetrical distributions and narrower
ranges in the fixed dose combination but this does not
reach statistical significance. This is in line with the obser-
vations made in the comparative pharmacokinetic study
in healthy volunteers in which it appears that the FDC
generates less variable results (P. Olliaro, V. Navaratnam;
personal communication).
Artesunate is converted rapidly to dihydroartemisinin
(DHA)  in vivo and most of the anti-malarial activity
derives from the metabolite. The pharmacokinetic param-
eter estimates of DHA and the total anti-malarial activity,
defined as the sum of the molar equivalent plasma levels
of DHA and AS, indicated rapid absorption and elimina-
tion. As noted in previous pharmacokinetic studies [23]
plasma levels were significantly higher following the first
dose when the patient was acutely ill than after subse-
quent doses when the patient was usually afebrile and
clinically improved. AUC and elimination half life were
halved for the third dose compared to the first dose. The
bioavailability from the co-formulated product was simi-
lar to that of the separate tablets. The higher rate of early
treatment failures observed in the FDC group is not con-
firmed neither in the efficacy study of children in Burkina
Faso (Sirima, 2009) nor in another multicenter study of
the FDC (Ndiaye, 2009). Both studies also showed similar
parasite clearance rates on Day-2 in the two treatments
groups. Poor drug absorption cannot be confirmed in the
five children with early treatment failure. Drug concentra-
Residuals plots for DHA pharmacokinetic population model: (A) observed versus fitted values; (B) residuals versus the fitted  values; (C) normal plot of residuals Figure 8
Residuals plots for DHA pharmacokinetic population model: (A) observed versus fitted values; (B) residuals 
versus the fitted values; (C) normal plot of residuals.
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Residuals plots for pharmacokinetic population model for the total anti-malarial activity: (A) observed versus 
fitted values; (B) residuals versus the fitted values; (C) normal plot of residuals.
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tions were available in two children: DHA level of 1202
ng/ml in one child measured at 2.1 hours and DHA level
of 620 ng/ml and artesunate level of 4.5 ng/ml in the sec-
ond child measured at 2 h. These drug levels are compara-
ble with values for other children (Figures 2 and 3).
However, the sparse nature of the data, the short half lives
of the drugs and the limitations of the population mode-
ling unable us to examine individual profiles and their
relation with the treatment outcome properly.
Associations were identified between outcome and
desethylamodiaquine levels on Day-7 and 14. Predicted
levels at Day-7 and Day-14 were significantly lower (p <
0.001) in patients with recurrent parasitaemia. For meas-
ured concentrations, the association was less clear, proba-
bly because of the low number of patients with plasma
levels available, but all patients with PCR confirmed
recrudescent parasitaemia or with recurrent parasitaemia
and missing PCR results had Day-7 concentrations below
75 ng/mL giving 100% cure rate in patients with Day-7
concentrations above 75 ng/mL. This cure rate was esti-
mated as 97% based on the estimated Day-7 concentra-
tions.
There was no indication of a relationship between high
blood concentrations of either drug and adverse effects.
Of the 10 patients with DeAq blood levels higher than
600 ng/ml post 3rd dose, only one had evidence of hepa-
tocellular injury that was probably AQ related and was
resolving by Day-28. Transient, AQ induced hepatocellu-
lar liver toxicity is well described and is probably a type II
immune reaction.
Although rates of absorption were not examined in detail
because of the sparse sampling, there were no obvious
major differences in the observed concentrations collected
during the absorption phase for the two drug formula-
tions. The elimination kinetics estimated from sparse data
may have missed a slower elimination phase and, there-
fore, underestimated the terminal elimination phase, but
this is unlikely to contribute significantly to the therapeu-
tic response. Importantly, the estimated bioavailability
from the co-formulated product was similar to that of the
separate tablets. Thus, if there is a longer terminal phase
of elimination, it is unlikely to start at different concentra-
tions with the two formulations.
Conclusion
These data support the pharmacological equivalence of
the new fixed dose AS/AQ formulation with the previ-
ously established separate products. The likely improved
adherence associated with this relatively well tolerated,
simply administered, stable (shelf life in tropical condi-
tions 3 years), inexpensive (cost below 0.5/1 USD for
child/adults for 3-day treatment) FDC should be a signif-
icant operational advantage.
List of abbreviations used
ACT: Artemisinin Combination Therapy; AQ: Amodi-
aquine; AS: Artesunate; AS/AQ: Artesunate and Amodi-
aquine in a fixed dose combination; AS+AQ: Artesunate
and Amodiaquine in a loose dose combination; DHA:
Dihydroartemisinin; DeAQ: Desethylamodiaquine; FDC:
Fixed-dose combination.
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